Guangzhou Innogen Pharmaceutical Group Co Ltd (HKSE:02591) Share Price

Company Profile

Business description
Guangzhou Innogen Pharmaceutical Group Co Ltd is a company in Asia to commercialize an innovative, humanized, long-acting glucagon-like peptide-1 (GLP-1) receptor agonist. It has commercialized Efsubaglutide Alfa (brand name: Diabegone), its Core Product, for the treatment of type 2 diabetes (T2D) in China. Its core business model is to discover, develop and commercialize innovative therapies for diabetes and other metabolic diseases. The company has built a pipeline of drug candidates targeting diabetes and other metabolic diseases.
Contact
No. 2 Tengfei Second Street
Room 409, Building H Self-numbered Creative Building
China-Singapore Guangzhou Knowledge City
Huangpu District, Guangdong Province
Guangzhou
CHN
https://www.innogenpharm.com
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
193

Recommended

Corning’s optical fiber business is thriving, and the Meta deal derisks its supply buildout, but success isn’t guaranteed.

Ananya Chag | 27 April 2026

From AI integration to capital expenditure increases, here’s what we expect in Alphabet’s earnings report.

Malik Ahmed Khan, CFA | 24 April 2026

Santos reports a solid quarter on the back of higher commodity prices - yet the shares look undervalued.

Mark Taylor | 24 April 2026

Index	Last price	Change	% Change
All Ordinaries	8,935.00	14.40	-0.16%
CAC 40	8,119.20	22.72	-0.28%
DAX 40	24,039.20	44.33	-0.18%
Dow JONES (US)	49,201.89	34.10	0.07%
FTSE 100	10,326.88	5.79	0.06%
HKSE	25,679.78	245.87	-0.95%
NASDAQ	24,605.47	281.63	-1.13%
Nikkei 225	59,917.46	619.90	-1.02%
NZX 50 Index	12,764.40	110.54	-0.86%
S&P 500	7,129.06	44.85	-0.63%
S&P/ASX 200	8,710.70	10.50	-0.12%
SSE Composite Index	4,078.64	7.71	-0.19%